Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Health Canada Informs Pregnant And Breastfeeding Women Not To Take Vitamin Maxum Matragen And/or Maxum Multi Vite Supplements
Health Canada is advising expectant mothers and breastfeeding women not to take the vitamin-mineral supplements Maxum Matragen or Maxum Multi-Vite by Seroyal International Inc. Maxum Multi-Vite has been approved as a vitamin-mineral supplement for only the general public but lacks the required cautionary statement on the label regarding pregnant and/or breast feeding women. The product Maxum Matragen is being promoted by the company as a prenatal supplement; however, neither product has been authorized for sale by Health Canada for use by women who are pregnant or breastfeeding. Don't forget to buy zoloft online no prescription.

Teens Are Exposed To Tobacco Content On Social Networking Sites
When teens surf the Internet, are they exposed to tobacco content or imagery? The study, "Exposure to Tobacco on the Internet: Content Analysis of Adolescents" Internet Use," tracked the Web pages viewed by 346 teens between the ages of 14 and 17 years. During a one-month period of data collection, these adolescents viewed 1.2 million Web pages. Of those pages, 0.72 percent contained tobacco or smoking content. Pro-tobacco content was found on 1,916 pages, anti-tobacco content on 1,572 pages, and complex and/or unclear content on 5,055 pages. Most of the tobacco-related content seen by teens was found on social networking sites. MySpace in particular represented 53 percent of the pages on which tobacco content was found. Previous studies have found a link between exposure to tobacco content in traditional media and adolescent smoking. The authors caution that as more communication occurs online in social networking sites, this may also impact adolescent smoking.

generic viagra online


News of the day
Older Cancer Patients Have More Frailty Than Other Seniors
Older people with a history of cancer are more likely to have disabilities and be frail and vulnerable than older adults who have not had cancer, according to a study in the Journal of the National Cancer Institute, published online July 29.
Public Health

Depomed Completes Enrollment Of Phase 3 Clinical Program Of DM-1796 In Post-Herpetic Neuralgia

Depomed, Inc. (NASDAQ:DEPO) announced that it has completed enrollment of the Phase 3 clinical trial of DM-1796 for the treatment of post-herpetic neuralgia. "We are glad that we successfully arrived at another milestone that brings Depomed closer to potential milestone payments related to the development of DM-1796 and further royalties and sales milestones upon its approval. We remain excited to have Solvay Pharmaceuticals as a strong and committed partner in the neuroscience field, we share with their expectation that DM-1796 could become a significant product for the treatment of neuropathic pain," said Carl A. Pelzel, Depomed"s president and chief executive officer. Dr. Michael Sweeney, Depomed"s vice president, Research and Development, added, " I would like to thank all clinical investigators, patients, and Depomed employees whose dedication to DM-1796 enabled us to complete enrollment as planned. We look forward to the top-line results of the trial in the fourth quarter of this year." Clinical Development Status In March 2008, Depomed initiated dosing of the first patient in this Phase 3 clinical trial for DM-1796 for PHN. The study is a randomized, double-blind, placebo-controlled study of approximately 450 PHN patients. Patients in the study are randomized into two treatment arms: placebo, or 1800mg of DM-1796 dosed once daily. Postherpetic Neuralgia (PHN) Postherpetic neuralgia (PHN) is a persistent neuropathic pain condition. It is caused by nerve damage after a shingles, or herpes zoster, viral infection and afflicts approximately one in five patients diagnosed with shingles (~ 150,000 individuals) in the U.S. The incidence of PHN increases in elderly patients, with 75 percent of those over 70 years old who have shingles developing PHN. The pain associated with PHN reportedly can be so severe that some patients are unable to resume normal activities for months. Leveraging Depomed"s Gastric Retentive Technology Gabapentin available on the market today is formulated for immediate release (IR). Upon ingestion, the entire administered dose is released into the stomach allowing for it to be rapidly absorbed into the blood. This rapid absorption leads to peak concentrations of the active ingredient, which gives rise to commonly experienced side effects including dizziness and daytime sleepiness. Patients taking immediate release formulations of gabapentin frequently need to take it three to four times a day to effectively manage their pain. Formulated with gastric retentive technology, DM-1796 is designed for targeted, controlled release to the upper GI tract over a six to eight hour period. This extended release allows for the drug to be gradually absorbed into the blood, reducing the likelihood of peak concentrations and potentially resulting in fewer side effects than seen with immediate release formulations. Greater treatment tolerability and a more convenient dosing regimen made possible with this technology could potentially translate into greater patient compliance and ultimately better pain management. About Depomed Depomed, Inc. is a specialty pharmaceutical company with two product candidates in Phase 3 clinical development, two approved products on the market and other product candidates in its early stage pipeline. Product candidate DM-1796 is in Phase 3 clinical development for the treatment of neuropathic pain and has been licensed to Solvay Pharmaceuticals. Product candidate SeradaTM is in Phase 3 clinical development for menopausal hot flashes. GLUMETZA® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Proquin® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of Acuform-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. Additional information about Depomed may be found on its website, www.depomed.com. Solvay Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009